Sequana Medical - FDA clears expansion of POSEIDON enrolment




07.10.21 12:18
Edison Investment Research

Sequana Medical announced on 4 October that it had received approval from the US FDA to expand patient recruitment in the pivotal cohort of its POSEIDON pivotal study to 70 (an increase of 10 patients). This decision should allow Sequana to meet its pre-defined target of having 40 evaluable patients for the primary efficacy analysis, and thus provide it with the desired statistical power to potentially meet the primary endpoint. In our view, the positive FDA decision reduces a degree of uncertainty with regards to the North American clinical programme, hence we raise our probability of success for alfapump in refractory and recurrent ascites in this market to 60% (from 55% previously). We now obtain a new pipeline rNPV of €246.4m (versus €219.8m, previously).




 
 
hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
6,88 € 7,00 € -0,12 € -1,71% 18.10./17:30
 
ISIN WKN Jahreshoch Jahrestief
BE0974340722 A2PD78 11,65 € 5,90 €
Handelsplatz Letzter Veränderung  Zeit
München 7,16 € 0,00%  08:11
Frankfurt 7,00 € -0,85%  08:17
Stuttgart 6,88 € -1,71%  10:55
  = Realtime
Aktien des Tages
  

Jetzt für den kostenfreien Newsletter "Aktien des Tages" anmelden und keinen Artikel unseres exklusiven Labels AC Research mehr verpassen.

Das Abonnement kann jederzeit wieder beendet werden.

Meistgelesene Artikel
Aktuelle Diskussionen
Es ist noch kein Thema vorhanden.
RSS Feeds




Bitte warten...